No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Checkpoint Therapeutics Insider Sold Shares Worth $1,076,412, According to a Recent SEC Filing
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)
Express News | FDA: Approval of Cosibelimab-Ipdl (Unloxcyt) Granted to Checkpoint Therapeutics
No Data